Standout Papers

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer... 2022 2026 2023 2024122
  1. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A (2022)
    Karen L. Reckamp, Mary W. Redman et al. Journal of Clinical Oncology

Immediate Impact

1 from Science/Nature 56 standout
Sub-graph 1 of 22

Citing Papers

The present and future of bispecific antibodies for cancer therapy
2024 Standout
Advances in targeting histone deacetylase for treatment of solid tumors
2024 Standout
4 intermediate papers

Works of Bryan A. Faller being referenced

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A
2022 Standout
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group
2021

Author Peers

Author Last Decade Papers Cites
Bryan A. Faller 307 167 189 32 496
Riccardo Ricotta 299 189 161 36 498
Nathalie Letarte 213 136 131 24 456
Ken Saijo 224 128 198 46 504
Fernanda I. Arnaldez 189 105 201 20 490
Pranshu Bansal 290 220 118 21 508
Olsi Gjyshi 156 142 191 23 519
Elsa Curtit 207 101 74 45 423
Manali Rupji 159 102 178 44 453
Daniele Pozzessere 226 170 111 24 416
Constanta Timcheva 372 89 125 23 457

All Works

Loading papers...

Rankless by CCL
2026